Medication linked to increased risk of inflammatory bowel disease

Medications that target tumor necrosis factor alpha (TNFα), a protein involved in inflammation, have revolutionized the management of certain autoimmune diseases, but paradoxically, these agents might provoke the development of other autoimmune conditions.

In an Alimentary Pharmacology & Therapeutics study of 17,018 individuals with who were treated with anti-TNFα medications—mostly infliximab, etanercept, and adalimumab—and 63,308 individuals who were not, treatment with etanercept, but not other anti?TNFα agents, was linked with an elevated risk of developing : a twofold increased risk of Crohn's disease and a twofold increased risk of ulcerative colitis.

"This study established that there is an increased risk of developing inflammatory bowel disease in individuals taking etanercept. Recognition of this phenomenon is important for clinicians taking care of these patients," said lead author Joshua Korzenik, MD, of Brigham and Women's Hospital, in Boston. "Perhaps more importantly, this study suggests that inflammatory bowel disease may be one of the auto-immune diseases that can be provoked by anti-TNFα agents. This suggests that there may be a common mechanism of immune dysregulation underpinning these diseases."


Explore further

A common anti-inflammatory therapy may help reduce risk of developing Parkinson's disease

More information: Joshua Korzenik et al, Increased risk of developing Crohn's disease or ulcerative colitis in 17 018 patients while under treatment with anti-TNFα agents, particularly etanercept, for autoimmune diseases other than inflammatory bowel disease, Alimentary Pharmacology & Therapeutics (2019). DOI: 10.1111/apt.15370
Provided by Wiley
Citation: Medication linked to increased risk of inflammatory bowel disease (2019, July 3) retrieved 20 July 2019 from https://medicalxpress.com/news/2019-07-medication-linked-inflammatory-bowel-disease.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
1 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more